Downloads: 338

Files in This Item:
File Description SizeFormat 
67_12_525.pdf800.44 kBAdobe PDFView/Open
Title: ニボルマブ再投与で治療効果を示した転移性腎細胞癌の1例
Other Titles: Successful Re-Administration of Nivolumab in Patient with Metastatic Renal Cell Carcinoma : A Case Report
Authors: 笹川, 甫  KAKEN_name
沼倉, 一幸  KAKEN_name
中村, 岳  KAKEN_name
久木元, 隆  KAKEN_name
菊池, 茜恵  KAKEN_name
提箸, 隆一郎  KAKEN_name
山本, 竜平  KAKEN_name
小泉, 淳  KAKEN_name
奈良, 健平  KAKEN_name
神田, 壮平  KAKEN_name
齋藤, 満  KAKEN_name
成田, 伸太郎  KAKEN_name
井上, 高光  KAKEN_name
佐藤, 滋  KAKEN_name
羽渕, 友則  KAKEN_name
Author's alias: SASAGAWA, Hajime
NUMAKURA, Kazuyuki
NAKAMURA, Gaku
KUKIMOTO, Takashi
KIKUCHI, Akane
SAGEHASHI, Ryuichiro
YAMAMOTO, Ryohei
KOIZUMI, Atsushi
NARA, Taketoshi
KANDA, Sohei
SAITO, Mitsuru
NARITA, Shintaro
INOUE, Takamitsu
SATOH, Shigeru
HABUCHI, Tomonori
Keywords: Renal cell carcinoma
Nivolumab
Re-administration
Neutrophil-to-lymphocyte ratio
Issue Date: 31-Dec-2021
Publisher: 泌尿器科紀要刊行会
Journal title: 泌尿器科紀要
Volume: 67
Issue: 12
Start page: 525
End page: 528
Abstract: A 46-year-old woman was referred to our hospital with a left-sided renal tumor pointed out by ultrasonography at the time of a medical checkup.Computed tomography revealed a mass measuring 88×77×68 mm on the upper pole of the left kidney. She was diagnosed with cT2aN0M0 clear cell renal cell carcinoma. Laparoscopic left nephrectomy was performed uneventfully. Histopathological diagnosis was clear cell renal cell carcinoma, G2, v1, pT2. Four months after surgery, lung metastases appeared, and systemic therapy was given sequentially as follows ; sunitinib for 2 months, nivolumab for 8 months, axitinib for 17 months, and pazopanib for 2 months.However, metastases progressed, and a re-administration of nivolumab was planned. The nivolumab re-treatment resulted in a marked reduction in multiple lung metastases despite the previous failure by nivolumab treatment. There are few reports on the therapeutic effect of re-administration of nivolumab. We report a case of successful treatment by re-administration of nivolumab.
Rights: 許諾条件により本文は2023/01/01に公開
DOI: 10.14989/ActaUrolJap_67_12_525
URI: http://hdl.handle.net/2433/267415
PubMed ID: 34991292
Appears in Collections:Vol.67 No.12

Show full item record

Export to RefWorks


Export Format: 


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.